CR9942A - Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) - Google Patents
Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)Info
- Publication number
- CR9942A CR9942A CR9942A CR9942A CR9942A CR 9942 A CR9942 A CR 9942A CR 9942 A CR9942 A CR 9942A CR 9942 A CR9942 A CR 9942A CR 9942 A CR9942 A CR 9942A
- Authority
- CR
- Costa Rica
- Prior art keywords
- flap
- activating protein
- lipoxygenase activating
- protein inhibitors
- lipoxygenase
- Prior art date
Links
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 abstract 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
Descritos en la presente estan compuestos y composiciones farmaceuticas conteniendo dichos compuestos, los cuales modulan la actividad de la proteina activadora de la 5-lipoxigenasa (FLAP)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73403005P | 2005-11-04 | 2005-11-04 | |
US74717406P | 2006-05-12 | 2006-05-12 | |
US82334406P | 2006-08-23 | 2006-08-23 | |
US11/553,946 US7977359B2 (en) | 2005-11-04 | 2006-10-27 | 5-lipdxygenase-activating protein (FLAP) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9942A true CR9942A (es) | 2008-10-29 |
Family
ID=38004604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9942A CR9942A (es) | 2005-11-04 | 2008-04-28 | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) |
Country Status (27)
Country | Link |
---|---|
US (3) | US7977359B2 (es) |
EP (2) | EP2404904A1 (es) |
JP (3) | JP4705986B2 (es) |
KR (1) | KR101031766B1 (es) |
CN (1) | CN102295637A (es) |
AT (1) | ATE530521T1 (es) |
AU (2) | AU2006311973B9 (es) |
BR (1) | BRPI0618046A2 (es) |
CA (1) | CA2628490C (es) |
CR (1) | CR9942A (es) |
CY (1) | CY1112383T1 (es) |
DK (1) | DK1943219T3 (es) |
EA (2) | EA015495B1 (es) |
ES (1) | ES2373977T3 (es) |
HK (1) | HK1114099A1 (es) |
HR (1) | HRP20120033T1 (es) |
IL (2) | IL190873A0 (es) |
MA (1) | MA29931B1 (es) |
MY (1) | MY151159A (es) |
NO (1) | NO342361B1 (es) |
NZ (2) | NZ567718A (es) |
PL (1) | PL1943219T3 (es) |
PT (1) | PT1943219E (es) |
RS (1) | RS52189B (es) |
SG (1) | SG166813A1 (es) |
SI (1) | SI1943219T1 (es) |
WO (1) | WO2007056021A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US8399666B2 (en) * | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US20100068301A1 (en) | 2006-11-30 | 2010-03-18 | Hutchinson John H | Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators |
TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
KR20160129109A (ko) * | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
US8618300B2 (en) | 2008-09-04 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
JP2012513406A (ja) * | 2008-12-23 | 2012-06-14 | パンミラ ファーマシューティカルズ,エルエルシー. | 皮膚科学の疾病の処置のためのflap阻害剤の局所製剤 |
CA2744898A1 (en) * | 2008-12-23 | 2010-07-01 | Amira Pharmaceuticals, Inc. | Topical formulations of flap inhibitors for administration to an eye |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
JP2013515677A (ja) * | 2009-09-23 | 2013-05-09 | アミラ ファーマシューティカルズ,インク. | 5−リポキシゲナーゼのインドリジンインヒビター |
JP2013506624A (ja) * | 2009-09-23 | 2013-02-28 | アミラ ファーマシューティカルズ,インク. | 5−リポキシゲナーゼのインドリジンインヒビター |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
WO2011054783A2 (en) * | 2009-11-03 | 2011-05-12 | Glaxo Group Limited | Novel processes |
PE20130751A1 (es) | 2010-08-16 | 2013-06-21 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrieno |
EP2609092B1 (en) * | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
JP5828188B2 (ja) * | 2010-09-23 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
AU2011305667A1 (en) * | 2010-09-23 | 2013-03-21 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
BR112013014019A2 (pt) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
EP3360552A1 (en) | 2010-12-07 | 2018-08-15 | Amira Pharmaceuticals, Inc. | Polycyclic lpa1 antagonist and uses thereof |
SG192582A1 (en) | 2011-01-30 | 2013-09-30 | Meiji Seika Pharma Co Ltd | Topical antifungal agent |
EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
WO2012166415A1 (en) | 2011-05-27 | 2012-12-06 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
JP6124892B2 (ja) | 2012-07-30 | 2017-05-10 | Meiji Seikaファルマ株式会社 | 抗白癬菌症貼付剤 |
MX2015001416A (es) | 2012-07-30 | 2015-05-08 | Meiji Seika Pharma Co Ltd | Agente liquido topico para el tratamiento de la dermatofitosis. |
WO2014031586A2 (en) * | 2012-08-20 | 2014-02-27 | Tallikut Pharmaceuticals, Inc. | Methods for treating cardiovascular diseases |
EP3906925A1 (en) | 2014-02-04 | 2021-11-10 | Bioscience Pharma Partners, LLC | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system |
US9533951B2 (en) * | 2014-10-20 | 2017-01-03 | Eastman Chemical Company | Heterocyclic amphoteric compounds |
MX2017011269A (es) | 2015-03-06 | 2018-01-12 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. |
CN105085401B (zh) * | 2015-08-17 | 2018-02-13 | 北京大学 | 六氢吲唑类15‑脂氧合酶激活剂及应用 |
EP4385571A2 (en) | 2016-09-07 | 2024-06-19 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor related applications |
KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
MY188809A (en) * | 2016-10-28 | 2022-01-05 | Astrazeneca Ab | Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide |
US20200147064A1 (en) * | 2017-02-16 | 2020-05-14 | Autoimmune Pharma Llc | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor |
EP3628669A1 (en) * | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
EP4377297A1 (en) * | 2021-07-30 | 2024-06-05 | The Regents of the University of California | Compounds for modulating epithelial 15-(s)-lipoxygenase-2 and methods of use for same |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2431491A1 (fr) | 1978-07-18 | 1980-02-15 | Delalande Sa | Nouveaux derives aminoalkoxy-5 benzofurannes et indoles, leur procede de preparation et leur application en therapeutique |
DK151884C (da) | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−3−カルボキサミド誘導体 |
US5109009A (en) | 1985-03-08 | 1992-04-28 | Leo Pharmaceutical Products Ltd. | Quinoline and pyridine compounds and inhibition of 5-lipoxygenases therewith |
IE58870B1 (en) | 1985-03-08 | 1993-11-17 | Leo Pharm Prod Ltd | Pyridine derivatives |
DE3632411A1 (de) | 1986-09-24 | 1988-04-07 | Merck Patent Gmbh | Verfahren zur herstellung von ethanderivaten |
IL84796A (en) | 1986-12-17 | 1992-03-29 | Merck Frosst Canada Inc | Substituted n-benzyl-indoles and pharmaceutical compositions containing them |
US5081138A (en) | 1986-12-17 | 1992-01-14 | Merck Frosst Canada, Inc. | 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith |
US5225421A (en) | 1986-12-17 | 1993-07-06 | Merck Frosst Canada, Inc. | 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor |
MY103259A (en) | 1987-04-15 | 1993-05-29 | Ici America Inc | Aliphatic carboxamides |
DE68904342T2 (de) | 1988-04-13 | 1993-05-06 | Ici America Inc | Cyclische amide. |
US5232916A (en) | 1988-06-27 | 1993-08-03 | Merck Frosst Canada, Inc. | Quinoline ether alkanoic acids |
CA1337427C (en) | 1989-08-22 | 1995-10-24 | Merck Frosst Canada Incorporated | (quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
NZ248177A (en) | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Benzyl phenyl hydrazine derivatives |
US5204344A (en) | 1989-08-22 | 1993-04-20 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
US5252585A (en) | 1992-02-03 | 1993-10-12 | Merck Frosst Canada, Inc. | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes |
US5272145A (en) | 1989-08-22 | 1993-12-21 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
NZ234883A (en) | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
US5420289A (en) | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
US5229516A (en) | 1989-10-27 | 1993-07-20 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
PT95692A (pt) | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
CA2032253C (en) | 1989-12-15 | 2000-11-28 | John W. Gillard | 5-lipoxygenase activating protein |
US5093356A (en) | 1990-01-16 | 1992-03-03 | Merck Frosst Canada, Inc. | Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
US5081145A (en) | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
US5095031A (en) | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
JPH0764841B2 (ja) | 1990-10-03 | 1995-07-12 | ファイザー製薬株式会社 | インドール誘導体およびその用途 |
US5182367A (en) | 1990-11-30 | 1993-01-26 | Merck & Co., Inc. | 5-lipoxygenase activating protein |
GB9108811D0 (en) | 1991-04-24 | 1991-06-12 | Erba Carlo Spa | N-imidazolyl derivatives of substituted indole |
US5202321A (en) | 1991-06-13 | 1993-04-13 | Merck Frosst Canada, Inc. | Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis |
JPH06100551A (ja) | 1991-09-06 | 1994-04-12 | Dainippon Ink & Chem Inc | 光学活性な2,5置換テトラヒドロフラン誘導体、その製造方法、その誘導体を含む液晶組成物及び液晶表示素子 |
US5273980A (en) | 1991-09-30 | 1993-12-28 | Merck Frosst Canada Inc. | Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
US5389650A (en) | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5190968A (en) | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
CA2079374C (en) | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5290798A (en) | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5308850A (en) | 1991-09-30 | 1994-05-03 | Merck Frosst Canada, Inc. | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
US5254567A (en) | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility |
AU3488693A (en) | 1992-02-13 | 1993-09-03 | Merck Frosst Canada Inc. | (Azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis |
CH683522A5 (de) | 1992-03-13 | 1994-03-31 | Hoffmann La Roche | Verfahren zur Herstellung von Diarylen. |
AU658729B2 (en) | 1992-03-27 | 1995-04-27 | Kyoto Pharmaceutical Industries, Ltd. | 3-(1H-imidazol-1-ylmethyl)-1H-indole derivatives |
DE69314786T2 (de) | 1992-05-13 | 1998-02-19 | Syntex Inc | Substituierte indole als angiotensin ii antagonisten |
JPH0658881A (ja) | 1992-06-12 | 1994-03-04 | Mitsubishi Rayon Co Ltd | 光学活性化合物の絶対配置判定法、絶対配置判定用試薬及び絶対配置判定装置 |
US5334719A (en) | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
WO1994000446A1 (en) | 1992-06-22 | 1994-01-06 | Merck Frosst Canada Inc. | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes |
US5314898A (en) | 1992-06-29 | 1994-05-24 | Merck & Co., Inc. | Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis |
US5314900A (en) | 1992-11-19 | 1994-05-24 | Merck Frosst Canada, Inc. | Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis |
US5288743A (en) | 1992-11-20 | 1994-02-22 | Abbott Laboratories | Indole carboxylate derivatives which inhibit leukotriene biosynthesis |
ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
JP3457694B2 (ja) | 1993-02-04 | 2003-10-20 | 第一製薬株式会社 | インフルエンザ感染予防・治療薬 |
US5374635A (en) | 1993-03-29 | 1994-12-20 | Merck Frosst Canada, Inc. | Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis |
IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
CA2164009A1 (en) | 1993-06-14 | 1994-12-22 | Robert L. Dow | Secondary amines as antidiabetic and antiobesity agents |
JPH075651A (ja) | 1993-06-14 | 1995-01-10 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
WO1995006637A1 (en) | 1993-09-03 | 1995-03-09 | Smithkline Beecham Plc | Indole and indoline derivatives as 5ht1d receptor antagonists |
DE4338770A1 (de) | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
US5399699A (en) | 1994-01-24 | 1995-03-21 | Abbott Laboratories | Indole iminooxy derivatives which inhibit leukotriene biosynthesis |
US5420282A (en) | 1994-02-15 | 1995-05-30 | Abbott Laboratories | Thiopyrano(2,3,4-c,d) indolyloxime ether alkylcarboxylates |
US5696076A (en) | 1994-06-22 | 1997-12-09 | Human Genome Sciences, Inc. | 5-lipoxygenase-activating protein II |
FR2721610B1 (fr) | 1994-06-28 | 1996-08-23 | Adir | Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JPH0820532A (ja) | 1994-07-05 | 1996-01-23 | Dai Ichi Seiyaku Co Ltd | 抗膵炎剤 |
CA2196046A1 (en) | 1994-07-27 | 1996-02-08 | Nigel Birdsall | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors |
TW396200B (en) | 1994-10-19 | 2000-07-01 | Sumitomo Chemical Co | Liquid crystal composition and liquid crystal element containing such composition |
TW321649B (es) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
AU4514496A (en) | 1994-12-13 | 1996-07-03 | Smithkline Beecham Corporation | Novel compounds |
US6069156A (en) | 1995-04-10 | 2000-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as cGMP-PDE inhibitors |
US5702637A (en) | 1995-04-19 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
EP0828712A1 (en) | 1995-05-10 | 1998-03-18 | Pfizer Inc. | Beta-adrenergic agonists |
JPH092977A (ja) | 1995-06-21 | 1997-01-07 | Dai Ichi Seiyaku Co Ltd | 経口投与用医薬組成物 |
GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
ATE216384T1 (de) | 1996-01-22 | 2002-05-15 | Fujisawa Pharmaceutical Co | Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten |
WO1997028105A1 (en) | 1996-01-29 | 1997-08-07 | Kaneka Corporation | Processes for the reduction of carbonyl compounds |
US5756531A (en) | 1996-04-30 | 1998-05-26 | Abbott Laboratories | Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis |
US5750558A (en) | 1996-06-06 | 1998-05-12 | Abbott Laboratories | Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis |
CA2261662A1 (en) | 1996-07-23 | 1998-01-29 | Daiichi Pharmaceutical Co., Ltd. | Sorbefacients |
US5877329A (en) | 1996-08-13 | 1999-03-02 | Merck & Co., Inc. | Palladium catalyzed indolization |
CN1237160A (zh) | 1996-11-14 | 1999-12-01 | 辉瑞大药厂 | 取代的吡啶的制备方法 |
GB9710523D0 (en) | 1997-05-23 | 1997-07-16 | Smithkline Beecham Plc | Novel compounds |
AU7552198A (en) | 1997-06-11 | 1998-12-30 | Sankyo Company Limited | Benzylamine derivatives |
JPH1180032A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 複合体 |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
RU2225397C2 (ru) | 1997-12-24 | 2004-03-10 | Авентис Фарма Дойчланд Гмбх | Производные индола как ингибиторы фактора Ха |
EP1043020A1 (en) | 1997-12-25 | 2000-10-11 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
JPH11193265A (ja) | 1997-12-26 | 1999-07-21 | Dai Ichi Seiyaku Co Ltd | 3−(7−アミジノ−2−ナフチル)−2−フェニルプロピオン酸誘導体の塩 |
JPH11189531A (ja) | 1997-12-26 | 1999-07-13 | Dai Ichi Seiyaku Co Ltd | 経粘膜投与用医薬組成物 |
CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
ID26123A (id) | 1998-02-25 | 2000-11-23 | Genetics Inst | Penghambat-penghambat phospholipase a2 |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
JP4472173B2 (ja) | 1998-04-15 | 2010-06-02 | セローノ ジェネティクス インスティテュート ソシエテ アノニム | 5−リポキシゲナーゼ活性化タンパク(flap)のゲノム配列、その多型マーカーおよび喘息の検出方法 |
JP2002516314A (ja) | 1998-05-22 | 2002-06-04 | サイオス インコーポレイテッド | 複素環式化合物ならびに心不全および他の疾患の処置方法 |
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
JP2000007590A (ja) | 1998-06-23 | 2000-01-11 | Daicel Chem Ind Ltd | 置換芳香族化合物の製造方法 |
CA2350415A1 (en) | 1998-11-18 | 2000-05-25 | Incyte Pharmaceuticals, Inc. | Inflammation-associated genes |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
JP2000302671A (ja) | 1999-04-27 | 2000-10-31 | Hitoshi Sezaki | 経口投与用医薬組成物 |
IL146309A0 (en) | 1999-05-21 | 2002-07-25 | Scios Inc | Indole-type derivatives as inhibitors of p38 kinase |
PL354923A1 (en) | 1999-09-21 | 2004-03-22 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
DE19948417A1 (de) | 1999-10-07 | 2001-04-19 | Morphochem Ag | Imidazol-Derivate und ihre Verwendung als Arzneimittel |
WO2001032621A1 (fr) | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif |
JP2001139462A (ja) | 1999-11-10 | 2001-05-22 | Dai Ichi Seiyaku Co Ltd | 新規製剤 |
MXPA02004594A (es) | 1999-11-16 | 2002-10-23 | Boehringer Ingelheim Pharma | Derivados de urea como agentes anti-inflamatorios. |
AU2050001A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Synthesis of indole-containing spla2 inhibitors |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
GB0003079D0 (en) | 2000-02-10 | 2000-03-29 | Glaxo Group Ltd | Novel protein |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
RU2259998C2 (ru) | 2000-03-09 | 2005-09-10 | Оно Фармасьютикал Ко., Лтд. | Производные индола, способ их получения и их применение |
US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
US20010039037A1 (en) | 2000-04-05 | 2001-11-08 | Lee Harland | Novel polypeptide |
WO2001077149A2 (en) | 2000-04-07 | 2001-10-18 | Bayer Aktiengesellschaft | Regulation of human cyslt2-like gpcr protein |
US6943174B2 (en) | 2000-06-14 | 2005-09-13 | Warner-Lambert Company | 6,5-Fused bicyclic heterocycles |
US7026318B2 (en) | 2000-06-29 | 2006-04-11 | Shionogi & Co., Ltd. | Compounds exhibiting X-type sPLA2 inhibiting effect |
DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
NZ525591A (en) | 2000-10-05 | 2004-04-30 | Fujisawa Pharmaceutical Co | Benzamide compounds as Apo B secretion inhibitors |
DK1355904T3 (da) | 2000-12-22 | 2007-10-15 | Wyeth Corp | Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander |
CN1289072C (zh) | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
JP2002226429A (ja) | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
JP4292402B2 (ja) | 2001-09-07 | 2009-07-08 | 小野薬品工業株式会社 | インドール誘導体化合物、それらの製造方法およびそれらを有効成分として含有する薬剤 |
CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
BR0212613A (pt) | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
DE10147672A1 (de) | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
WO2003050174A1 (en) | 2001-12-11 | 2003-06-19 | Rhodia Chimie | Catalytic pgm mixture for hydrosilylation |
USH2153H1 (en) | 2002-04-24 | 2006-04-04 | Smithkline Beecham Corp. | Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor |
EP1504755A1 (en) | 2002-05-13 | 2005-02-09 | Daiichi Pharmaceutical Co., Ltd. | Lyophilization product |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
CA2490715A1 (en) | 2002-06-20 | 2003-12-31 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing vinyl perfluoroalkanesulfonate derivative |
MY135686A (en) | 2002-06-24 | 2008-06-30 | Schering Corp | Indole derivatives useful as histamine h3 antagonists |
CN1671639A (zh) | 2002-08-23 | 2005-09-21 | 康涅狄格大学 | 新型联苯***素和类似联苯的***素 |
AU2003260025A1 (en) | 2002-08-26 | 2004-03-11 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
AU2003292508A1 (en) | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
US20040198800A1 (en) | 2002-12-19 | 2004-10-07 | Geoffrey Allan | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
GB0301350D0 (en) | 2003-01-21 | 2003-02-19 | Merck Sharp & Dohme | Therapeutic agents |
JP4513351B2 (ja) | 2003-02-12 | 2010-07-28 | チッソ株式会社 | 結合基にフッ素化されたアルキル基を有する液晶性化合物、液晶組成物および液晶表示素子 |
JPWO2004078719A1 (ja) | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
WO2004108671A1 (en) | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
AU2004259747B2 (en) | 2003-07-24 | 2009-02-19 | Merck Frosst Canada Ltd | Diphenyl substituted Cycloalkanes, compositions containing such compounds and methods of use |
WO2005019381A1 (en) | 2003-08-25 | 2005-03-03 | Merck Patent Gmbh | Liquid crystalline medium |
US7405300B2 (en) | 2003-09-04 | 2008-07-29 | Aventis Pharmaveuticals Inc. | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) |
ZA200601978B (en) | 2003-09-05 | 2007-05-30 | Neurogen Corp | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
JP4363133B2 (ja) | 2003-09-09 | 2009-11-11 | 東洋インキ製造株式会社 | 有機エレクトロルミネッセンス用素子材料およびそれを用いた有機エレクトロルミネッセンス素子 |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
DK1678185T3 (da) | 2003-10-31 | 2008-12-08 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose |
JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
ES2299906T3 (es) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
EP1690538A4 (en) | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
CN1886372A (zh) | 2003-12-03 | 2006-12-27 | 默克公司 | 用于治疗阿尔茨海默病及相关病症的1-烷基-3-硫-取代的吲哚-2-链烷酸 |
US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
JP5142450B2 (ja) | 2003-12-25 | 2013-02-13 | 徹也 西尾 | ジアミノ化合物、ビニル化合物、高分子化合物、配向膜、該配向膜を用いた有機半導体装置、導電性高分子、該導電性高分子を使用したエレクトロルミネッセンス素子、液晶配向膜、及び該液晶配向膜を用いた光学素子 |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
WO2005066157A1 (en) | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
JP2005194250A (ja) | 2004-01-09 | 2005-07-21 | Sumitomo Chemical Takeda Agro Co Ltd | トリアゾール化合物、その製造法および用途 |
US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
WO2005082346A1 (en) | 2004-02-26 | 2005-09-09 | Merck & Co, Inc. | Use of cysteinyl leukotriene 2 receptor antagonists |
WO2005097203A2 (en) | 2004-04-01 | 2005-10-20 | Cardiome Pharma Corp. | Serum protein conjugates of ion channel modulating compounds and uses thereof |
CN101031289A (zh) | 2004-04-26 | 2007-09-05 | 范德比尔特大学 | 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物 |
DE602005015962D1 (de) | 2004-05-03 | 2009-09-24 | Hoffmann La Roche | Indolylderivate als liver-x-rezeptormodulatoren |
US20080188473A1 (en) | 2004-06-18 | 2008-08-07 | Kristofer Olofsson | Indoles Useful in the Treatment of Inflammation |
CN1980659A (zh) | 2004-07-02 | 2007-06-13 | 默克公司 | 具有抗糖尿病活性的吲哚类 |
US8207172B2 (en) | 2004-08-20 | 2012-06-26 | Bayer Intellectual Property Gmbh | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
WO2006044602A2 (en) | 2004-10-18 | 2006-04-27 | Merck & Co., Inc. | Diphenyl substituted alkanes as flap inhiibitors |
CA2594422A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
CA2594773A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US20080249091A1 (en) | 2005-01-19 | 2008-10-09 | Benjamin Pelcman | Indoles Useful in the Treatment of Inflammation |
CN101142185A (zh) | 2005-01-19 | 2008-03-12 | 比奥里波克斯公司 | 用于炎症治疗的吲哚 |
US20100197687A1 (en) | 2005-01-19 | 2010-08-05 | Benjamin Pelcman | Indoles Useful in the Treatment of Inflammation |
CA2600860A1 (en) | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
BRPI0610035A2 (pt) | 2005-04-21 | 2010-05-18 | Serono Lab | sulfonamidas de pirazina 2,3 substituìdas |
PT1888033E (pt) | 2005-06-09 | 2014-05-15 | Meda Ab | Método e composição para tratamento de distúrbios inflamatórios |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
AU2006279325B2 (en) | 2005-08-18 | 2013-06-27 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
US7394658B2 (en) | 2005-09-01 | 2008-07-01 | Harman International Industries, Incorporated | Heat sink with twist lock mounting mechanism |
ES2379987T3 (es) | 2005-10-11 | 2012-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
CA2626549A1 (en) | 2005-10-21 | 2007-04-26 | University Of Alabama At Birmingham | Small molecule inhibitors of hiv-1 capsid assembly |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
US20070244128A1 (en) | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
UY29896A1 (es) | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
UY29892A1 (es) | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
AR059901A1 (es) | 2006-03-20 | 2008-05-07 | Bayer Pharmaceuticals Corp | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
JP5564251B2 (ja) | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
JP2009023986A (ja) | 2006-11-08 | 2009-02-05 | Pharma Ip | 抗癌剤としてのビアリール誘導体 |
AU2007321719B2 (en) | 2006-11-15 | 2013-11-21 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
US20100068301A1 (en) | 2006-11-30 | 2010-03-18 | Hutchinson John H | Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators |
EP2114876A4 (en) | 2007-02-05 | 2010-12-22 | Amira Pharmaceuticals Inc | INVERSE INDOLES AS INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP) |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
WO2009002746A1 (en) | 2007-06-22 | 2008-12-31 | Decode Genetics Ehf. | Dosing schedules of leukotriene synthesis inhibitors for human therapy |
WO2009009041A2 (en) | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US20100298343A1 (en) | 2007-10-05 | 2010-11-25 | John Howard Hutchinson | 5-lipoxygenase-activating protein (flap) inhibitors |
TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
EP2269076A4 (en) | 2008-03-14 | 2011-04-06 | Nat Jewish Health | METHODS FOR DETERMINING SENSITIVITY TO TREATMENT WITH LEUCOTRIENE MODIFIERS |
KR20160129109A (ko) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
-
2006
- 2006-10-27 US US11/553,946 patent/US7977359B2/en not_active Expired - Fee Related
- 2006-10-30 WO PCT/US2006/042690 patent/WO2007056021A2/en active Application Filing
- 2006-10-30 AU AU2006311973A patent/AU2006311973B9/en not_active Ceased
- 2006-10-30 EP EP11171816A patent/EP2404904A1/en not_active Withdrawn
- 2006-10-30 NZ NZ567718A patent/NZ567718A/en not_active IP Right Cessation
- 2006-10-30 NZ NZ592541A patent/NZ592541A/xx not_active IP Right Cessation
- 2006-10-30 RS RS20120006A patent/RS52189B/en unknown
- 2006-10-30 SG SG201008041-4A patent/SG166813A1/en unknown
- 2006-10-30 EP EP06836773A patent/EP1943219B8/en active Active
- 2006-10-30 EA EA200801163A patent/EA015495B1/ru not_active IP Right Cessation
- 2006-10-30 PL PL06836773T patent/PL1943219T3/pl unknown
- 2006-10-30 SI SI200631225T patent/SI1943219T1/sl unknown
- 2006-10-30 CA CA2628490A patent/CA2628490C/en not_active Expired - Fee Related
- 2006-10-30 CN CN201110179642A patent/CN102295637A/zh active Pending
- 2006-10-30 ES ES06836773T patent/ES2373977T3/es active Active
- 2006-10-30 MY MYPI20081429 patent/MY151159A/en unknown
- 2006-10-30 AT AT06836773T patent/ATE530521T1/de active
- 2006-10-30 BR BRPI0618046-9A patent/BRPI0618046A2/pt not_active Application Discontinuation
- 2006-10-30 EA EA201000584A patent/EA018616B1/ru not_active IP Right Cessation
- 2006-10-30 KR KR1020087013547A patent/KR101031766B1/ko active IP Right Grant
- 2006-10-30 DK DK06836773.9T patent/DK1943219T3/da active
- 2006-10-30 PT PT06836773T patent/PT1943219E/pt unknown
- 2006-10-30 JP JP2008539007A patent/JP4705986B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-15 IL IL190873A patent/IL190873A0/en not_active IP Right Cessation
- 2008-04-16 NO NO20081838A patent/NO342361B1/no not_active IP Right Cessation
- 2008-04-28 CR CR9942A patent/CR9942A/es unknown
- 2008-05-05 MA MA30900A patent/MA29931B1/fr unknown
- 2008-08-25 HK HK08109452.4A patent/HK1114099A1/xx not_active IP Right Cessation
-
2009
- 2009-12-04 JP JP2009276800A patent/JP5451347B2/ja not_active Expired - Fee Related
-
2010
- 2010-11-10 AU AU2010241356A patent/AU2010241356B2/en not_active Ceased
-
2011
- 2011-01-24 US US13/012,045 patent/US20110118315A1/en not_active Abandoned
- 2011-01-28 JP JP2011015870A patent/JP5506707B2/ja active Active
- 2011-05-24 IL IL213107A patent/IL213107A0/en unknown
-
2012
- 2012-01-10 HR HR20120033T patent/HRP20120033T1/hr unknown
- 2012-01-11 CY CY20121100021T patent/CY1112383T1/el unknown
-
2013
- 2013-07-16 US US13/942,934 patent/US8710081B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9942A (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
ECSP20027480A (es) | Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
EA200801164A3 (ru) | Ингибиторы протеина, активирующего 5-липоксигеназу (flap) | |
CR20120421A (es) | Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa | |
EA200901308A1 (ru) | Ингибиторы белка, активирующего 5-липоксигеназу (flap) | |
ECSP088759A (es) | Composiciones farmacéuticas | |
UY31073A1 (es) | Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap) | |
CR10094A (es) | Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
CY1113199T1 (el) | Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης | |
ATE525372T1 (de) | Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen | |
GT200600316A (es) | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
ATE492545T1 (de) | Verbindungen und zusammensetzungen als proteinkinase-hemmer | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
ECSP077335A (es) | Inhibidores de la interaccion entre mdm2 y p53 | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
CR20130216A (es) | Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa | |
CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
DK1812895T3 (da) | Stofkilde | |
ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
AR066042A1 (es) | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) | |
EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos |